InnoSer News
MDX Mouse Model Validation Data
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Project Completion Announcement: CARDIOIDS Collaboration with Professor Leon de Windt Advances Arrhythmogenic Cardiomyopathy (ACM) Research
In its role as an industry research partner, InnoSer is pleased to announce the successful completion of the CARDIOIDS project, a consortium-led initiative led by Professor Leon de Windt at Maastricht University. This project represents a major milestone in...
InnoSer and TissUse Sign Strategic Co-Marketing Agreement to Advance Microphysiological Systems (MPS) Applications in Drug Development
InnoSer, a leading preclinical contract research organization (CRO), and TissUse, a pioneer in the field of microphysiological systems (MPS) development, are pleased to announce the signing of a strategic co-marketing agreement aimed at promoting the widespread...
Therapeutic targets for ADPKD
In ADPKD, mutations in the PKD1 or PKD2 gene cause changes in polycystin 1 or 2 (PC1 and PC2) expression, which in turn interferes with several intracellular signaling pathways that are e.g., involved in cell proliferation, fluid secretion, and ciliary function. The...
InnoSer completes a major milestone in the HEAL project with validated tumorigenicity assay
In a significant achievement, InnoSer has successfully validated tumorigenicity assay as part of the HEAL project, a major initiative aimed at accelerating the development of an allogeneic iPSC-based heart therapy. This milestone lays out the groundwork for safe and...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading...
Invitation: Meet InnoSer at the upcoming Society for Neuroscience 2024 Chicago Meeting
We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO) will be actively participating in the upcoming Society for Neuroscience 2024 Conference taking place in Chicago, US from Saturday 5th to 9th of October. ...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Introduction to InnoSer’s Preclinical Epilepsy Research CRO Platform
Preclinical epilepsy-related research with InnoSer Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
Phenotyping of a C3-PMP22 mouse model of CMT1A
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...